A central goal of the NCT is molecularly guided patient stratification as the basis for individualized treatment decisions in somatic and hereditary cancers. By leveraging the expertise of NCT, DKFZ, and DKTK in multidimensional tumor characterization and molecular mechanism-based therapy, NCT has developed a standard for (1) comprehensive molecular profiling, (2) clinical interpretation of molecular data, (3) functional analysis of primary patient samples, (4) treatment decision making in molecular tumor boards, (5) longitudinal clinical data collection and (6) clinical trial design and conduct. The current workflow is being expanded by additional layers of patient characterization, such as genome-wide DNA methylation profiling, which has substantially advanced the diagnosis and classification of brain tumors and sarcomas. To improve clinical translation, a portfolio of molecularly guided clinical trials has been developed, and the biological stratification approach will be extended to additional treatment modalities.
Molecular stratification programs such as MASTER, a registry for young adults with advanced cancer across histologies and adults with rare tumors across age groups, recruit more than 400 patients per year. Potentially actionable findings are discussed in molecular tumor boards, including participants from the NCT Heidelberg, the NCT Dresden, and all DKTK (German Cancer Consortium) partner sites, to determine therapeutic choices for individual patients. Towards the goal of systematic clinical translation, the molecular profiling platforms are linked to a range of investigator initiated trials (IITs), such as the NCT PMO (Personalized Medical Oncology) studies, which are coordinated by the Clinical Trial Center at NCT Heidelberg.
Other specialized stratification programs focus on specific cancer types such as CATCH (advanced breast cancer), COGNITION (early-stage breast cancer), and N2M2 (glioblastoma) and provide whole-exome/genome and RNA sequencing when standard treatment has failed and routine molecular diagnostics have yielded no actionable target.